Consistent Biochemical Data are Essential for Comparability of Botulinum Toxin Type A Products

  title={Consistent Biochemical Data are Essential for Comparability of Botulinum Toxin Type A Products},
  author={A. Pickett},
  journal={Drugs in R\&D},
  pages={97 - 98}
The recent article from Dr Frevert of Merz,[1] together with the accompanying commentary from Dr Sesardic of NIBSC,[2] makes a new contribution to the data available for clinical botulinum toxin type A (BoNT-A) products. However, in addition to the comments about the various technical aspects of the data provided by Dr Frevert, as described by Dr Sesardic,[2] one important and key factor about the BoNT-A products has not been mentioned. The units of each product are different, not… Expand
Clinical Relevance of Botulinum Toxin Immunogenicity
Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data
Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products
Botulinum neurotoxin formulations: overcoming the confusion
Botulinum Toxin as a Clinical Product: Manufacture and Pharmacology
Clinical Applications of Botulinum Neurotoxin
  • K. Foster
  • Chemistry
  • Current Topics in Neurotoxicity
  • 2014
Botulinum Toxin in Aesthetic Medicine: Myths and Realities


Comparison of type a botulinum toxin products in clinical use
Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications
  • A. Pickett, S. Dodd, B. Rzany
  • Medicine
  • Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
  • 2008
Studies on the dissociation of botulinum neurotoxin type A complexes.
Dysport: pharmacological properties and factors that influence toxin action.
  • A. Pickett
  • Biology, Medicine
  • Toxicon : official journal of the International Society on Toxinology
  • 2009
Analysis of genomic differences among Clostridium botulinum type A1 strains